Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893113 | 0.84 | HPGD (0.44) | HPGDHSD17B10ALDH1A1KDM4EGAA | |
| SCHEMBL14008505 | 0.82 | HPGD (0.47) | HPGDHSD17B10ALDH1A1ACHEALOX15 | |
| SCHEMBL7890511 | 0.81 | HRH3 (0.39) | HPGDHRH3RAPGEF4CYP11B1CYP11B2 | |
| SCHEMBL19243066 | 0.81 | HPGD (0.40) | HPGDHSD17B10HRH3ALDH1A1 | |
| SCHEMBL23638591 | 0.80 | HPGD (0.42) | HPGDHSD17B10HTR1DHTR1BALDH1A1 | |
| SCHEMBL11930746 | 0.80 | HPGD (0.42) | HPGDHSD17B10ALDH1A1KDM4EGAA | |
| SCHEMBL13626758 | 0.80 | HPGD (0.42) | HPGDHSD17B10ALDH1A1KDM4EGAA | |
| SCHEMBL15216746 | 0.80 | ALDH1A1 (0.46) | HPGDHSD17B10ALDH1A1ACHE | |
| SCHEMBL12895706 | 0.78 | HPGD (0.41) | HPGDHSD17B10RAPGEF4KDM4E | |
| SCHEMBL12595154 | 0.78 | L3MBTL1 (0.35) | HPGDHSD17B10HRH3RAPGEF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20210363164-A1 | Hydroxide-Catalyzed Formation Of Silicon-Oxygen Bonds By Dehydrogenative Coupling Of Hydrosilanes And Alcohols | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2021-11-25 | — | — | US | disclosed |
| US-20170029447-A1 | HYDROXIDE-CATALYZED FORMATION OF SILICON-OXYGEN BONDS BY DEHYDROGENATIVE COUPLING OF HYDROSILANES AND ALCOHOLS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-02-02 | — | — | US | disclosed |
| US-8569349-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8338637-B2 | Glaucoma; prostaglandin receptor modulators; cyclopentyl compounds such as 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid | ALLERGAN, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8252788-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8003680-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110178084-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7737140-B2 | Eicosanoid derivatives used in the treatment of glaucoma, inflammatory bowel disease and alopecia | ALLERGAN, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100048669-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-1997012902-A1 | THIO-SUBSTITUTED PEPTIDES AS INHIBITORS FOR METALLOPROTEINASES AND TNF LIBERATION | DARWIN DISCOVERY LIMITED (GB) | 1997-04-10 | — | — | WO | disclosed |
| WO-1997012861-A1 | MERCAPTOAMIDE DERIVATIVES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1997-04-10 | — | — | WO | disclosed |
| WO-1997012887-A1 | PURINE AND GUANINE DERIVATIVES AS PNP INHIBITORS | CHIROSCIENCE LIMITED (GB) | 1997-04-10 | — | — | WO | disclosed |
| WO-1996035711-A1 | PEPTIDE COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION, AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035712-A1 | PEPTIDYL COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035687-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035714-A1 | PEPTIDE COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION AND THEIR THERAPEUTIC USES | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996011200-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011209-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| WO-1991007378-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE DIURETIC AGENTS | PFIZER LIMITED (GB) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363164-A1 | Hydroxide-Catalyzed Formation Of Silicon-Oxygen Bonds By Dehydrogenative Coupling Of Hydrosilanes And Alcohols | SORD, ADH1A, ADH1C | HPGD 407/4885HSD17B10 91/4885HRH3 20/4885 |
| US-20100048669-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, GOT1 | HPGD 419/4885HSD17B10 1840/4885HRH3 1746/4885 |
| US-20170029447-A1 | HYDROXIDE-CATALYZED FORMATION OF SILICON-OXYGEN BONDS BY DEHYDROGENATIVE COUPLING OF HYDROSILANES AND ALCOHOLS | SORD, ADH1A, ADH1C | HPGD 407/4885HSD17B10 91/4885HRH3 20/4885 |
| US-20110178084-A1 | THERAPEUTIC COMPOUNDS | DDO, QDPR, SLC10A1 | HPGD 734/4885HSD17B10 2539/4885HRH3 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.